



Opoid Agonist Treatment Training Programs

Purpose

This Regulatory Statement specifies the training programs approved by the Board for the purposes of sections 3(a) and 4(a) of Schedule E.12 of the bylaws of the College under the *Health Professions and Occupations Act* (“HPOA”).

Background

Schedule E.12 of the HPOA bylaws provides guidance to licensees who are employed in a community pharmacy that provides pharmacy services related to opioid agonist treatment, or that provides injectable opioid agonist treatment, for opioid use disorder.

Sections 3 and 4 of Schedule E.12 of the HPOA bylaws require pharmacists and pharmacy technicians to successfully complete a training program approved by the Board and record a self-declaration of training completion in eServices.

Requirements

1. All pharmacy managers, staff pharmacists, and relief pharmacists employed in a community pharmacy that provides pharmacy services related to buprenorphine/naloxone maintenance treatment (“BMT”), methadone maintenance treatment (“MMT”) or slow release oral morphine (“SROM”) maintenance treatment must successfully complete the British Columbia Pharmacy Association (“BCPhA”) Opioid Agonist Treatment Compliance and Management Program for Pharmacy (“OATCAMPP”) training program
2. All pharmacy technicians employed in a community pharmacy that provides pharmacy services related to BMT, MMT or SROM maintenance treatment must successfully complete the online component of the BCPhA OAT-CAMPP training program.

Legislation

- HPOA s. 72(3)
- HPOA bylaws Schedule E.12 – Practice Standards: Opioid Agonist Treatment

Additional Information

n/a

RS Number:	26-004
Approved by:	Board
First approved:	27 Feb 2026
Effective:	01 Apr 2026
Revised:	n/a
Version:	1.0
